Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study [Yahoo! Finance]
Neumora Therapeutics, Inc. (NMRA)
Company Research
Source: Yahoo! Finance
therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). NMRA-266 is a positive allosteric modulator (PAM) of the M4 muscarinic receptor and is part of the Company's M4 PAM franchise. The clinical hold determination follows recently available pre-clinical data showing convulsions in rabbits. Following this action, the Phase 1 single ascending dose / multiple ascending dose study with NMRA-266 has been paused. Approximately 30 participants have been dosed in the Phase 1 study, with no evidence of convulsions observed in any participant. Neumora is working with the FDA to evaluate the potential to resolve the clinical hold. While these discussions with the Agency are ongoing, the Company's prior guidance regarding NMRA-266 is no longer applicable. Neumora will provide an update on NMRA-266 when available. Neumora's M
Show less
Read more
Impact Snapshot
Event Time:
NMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NMRA alerts
High impacting Neumora Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NMRA
News
- Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Neumora Therapeutics to Participate in Upcoming Conferences in May [Yahoo! Finance]Yahoo! Finance
- Neumora Therapeutics to Participate in Upcoming Conferences in MayGlobeNewswire
- We're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely [Yahoo! Finance]Yahoo! Finance
NMRA
Earnings
- 3/7/24 - Miss
NMRA
Sec Filings
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- 4/25/24 - Form DEFA14A
- NMRA's page on the SEC website